HIV raises anal cancer risk in women, study says

April 16, 2012
HIV raises anal cancer risk in women, study says
Findings indicate gay men aren't only ones who need screening.

(HealthDay) -- Women with HIV are at increased risk for anal cancer, a new study finds.

Researchers at Montefiore Medical Center in New York City looked at 715 HIV-infected women and found that 10.5 percent had some form of anal disease and about one-third of those women had precancerous disease.

"Anal cancer was widely associated with HIV-infected men who have sex with men. But now, this study reveals anal precancerous disease in a high proportion of women with HIV," Dr. Mark Einstein, director of in the division of gynecologic oncology and a professor at College of Medicine, said in a Montefiore news release.

The increased risk of anal cancer in HIV-infected women is likely because HIV is associated with (HPV), which causes nearly all anal cancers, the researchers said.

The study appears May 1 in the Journal of AIDS.

The researchers said their findings suggest that all HIV-infected women who have abnormal findings on tests of anal should be referred for high resolution anoscopy, a visual examination of the inside of the anus.

In addition, all HIV-infected women and men should be considered for anal cancer screening, the researchers said.

Explore further: Most anal lesions don't cause cancer in men, research shows

More information: The U.S. National Cancer Institute has more about anal cancer.

Related Stories

Most anal lesions don't cause cancer in men, research shows

March 23, 2012
(HealthDay) -- Anal human papillomavirus (HPV) infection and precancerous lesions are common among gay and bisexual men, but most of these cases will not progress to anal cancer, a new analysis of earlier research shows.

Cervical vaccine also protects against anal cancer risk

August 23, 2011
A vaccine routinely used to shield against cervical cancer caused by the human papillomavirus also reduces women's risk of anal cancer, a study published by the journal The Lancet Oncology on Tuesday says.

Clinical trial shows first evidence that anal cancer is preventable

October 26, 2011
A large, international clinical trial led by doctors at the University of California, San Francisco indicates that a vaccine to prevent anal cancer is safe and effective, according to a study reported in the Oct. 27, 2011 ...

Recommended for you

Researchers find latent HIV reservoirs inherently resistant to elimination by CD8+ T-cells

January 22, 2018
The latest "kick-and-kill" research to eliminate the HIV virus uncovered a potential obstacle in finding a cure. A recent study by researchers at the George Washington University (GW) found that latent HIV reservoirs show ...

HIV-1 genetic diversity is higher in vaginal tract than in blood during early infection

January 18, 2018
A first-of-its-kind study has found that the genetic diversity of human immunodeficiency virus type 1 (HIV-1) is higher in the vaginal tract than in the blood stream during early infection. This finding, published in PLOS ...

War in Ukraine has escalated HIV spread in the country: study

January 15, 2018
Conflict in Ukraine has increased the risk of HIV outbreaks throughout the country as displaced HIV-infected people move from war-affected regions to areas with higher risk of transmission, according to analysis by scientists.

Researchers offer new model for uncovering true HIV mortality rates in Zambia

January 12, 2018
A new study that seeks to better ascertain HIV mortality rates in Zambia could provide a model for improved national and regional surveillance approaches, and ultimately, more effective HIV treatment strategies.

New drug capsule may allow weekly HIV treatment

January 9, 2018
Researchers at MIT and Brigham and Women's Hospital have developed a capsule that can deliver a week's worth of HIV drugs in a single dose. This advance could make it much easier for patients to adhere to the strict schedule ...

New long-acting, less-toxic HIV drug suppresses virus in humanized mice

January 8, 2018
A team of Yale researchers tested a new chemical compound that suppresses HIV, protects immune cells, and remains effective for weeks with a single dose. In animal experiments, the compound proved to be a promising new candidate ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.